Short Interest in Aileron Therapeutics, Inc. (NASDAQ:ALRN) Decreases By 41.3%

Aileron Therapeutics, Inc. (NASDAQ:ALRN) was the recipient of a large decline in short interest in the month of June. As of June 15th, there was short interest totalling 140,400 shares, a decline of 41.3% from the May 31st total of 239,200 shares. Based on an average trading volume of 110,200 shares, the short-interest ratio is presently 1.3 days. Currently, 0.7% of the shares of the company are short sold.

Analysts Set New Price Targets

ALRN has been the subject of several recent analyst reports. Brookline Capital Management raised shares of Aileron Therapeutics to a “strong-buy” rating in a report on Thursday, May 30th. LADENBURG THALM/SH SH upped their target price on shares of Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, April 18th.

Insider Activity

In other news, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total transaction of $30,361.50. Following the completion of the sale, the insider now owns 1,753,156 shares of the company’s stock, valued at approximately $5,697,757. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, major shareholder Of Texas/Texas Am I. University sold 9,342 shares of the business’s stock in a transaction on Wednesday, June 12th. The shares were sold at an average price of $3.25, for a total transaction of $30,361.50. Following the completion of the sale, the insider now owns 1,753,156 shares of the company’s stock, valued at approximately $5,697,757. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the business’s stock in a transaction on Wednesday, May 1st. The shares were sold at an average price of $4.21, for a total transaction of $85,526.15. Following the sale, the insider now directly owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The disclosure for this sale can be found here. Insiders sold a total of 64,618 shares of company stock valued at $248,685 in the last 90 days. Company insiders own 5.57% of the company’s stock.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Aileron Therapeutics stock. Sigma Planning Corp acquired a new stake in shares of Aileron Therapeutics, Inc. (NASDAQ:ALRN) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 16,580 shares of the company’s stock, valued at approximately $51,000. Sigma Planning Corp owned about 0.34% of Aileron Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 90.89% of the company’s stock.

Aileron Therapeutics Stock Down 1.4 %

Shares of ALRN traded down $0.04 during midday trading on Friday, hitting $2.86. 10,795 shares of the company traded hands, compared to its average volume of 75,227. The firm has a 50 day moving average of $3.66 and a 200-day moving average of $4.31. Aileron Therapeutics has a 52 week low of $1.01 and a 52 week high of $7.42.

Aileron Therapeutics (NASDAQ:ALRN) last released its quarterly earnings data on Monday, May 20th. The company reported ($0.86) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.72). Analysts forecast that Aileron Therapeutics will post -0.93 earnings per share for the current fiscal year.

Aileron Therapeutics Company Profile

Aileron Therapeutics, Inc, a biopharmaceutical company, focuses on developing medicines to address unmet medical needs in orphan pulmonary and fibrosis indications in the United States. The company's lead product candidate is LTI-03, a peptide, which is in Phase 1b clinical trial for the treatment of idiopathic pulmonary fibrosis (IPF).